News
NBY
0.5299
+5.12%
0.0258
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
Barchart · 4d ago
Weekly Report: what happened at NBY last week (1209-1213)?
Weekly Report · 6d ago
Weekly Report: what happened at NBY last week (1202-1206)?
Weekly Report · 12/09 12:24
NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting
Barchart · 12/09 05:50
Weekly Report: what happened at NBY last week (1125-1129)?
Weekly Report · 12/02 12:24
Weekly Report: what happened at NBY last week (1118-1122)?
Weekly Report · 11/25 12:12
NovaBay Pharmaceuticals To Reconvene Special Meeting Of Stockholders To December 18, 2024; Initial Meeting Adjourned Due To Insufficient Votes To Reach The 50% Threshold Of Outstanding Common Shares Voting In Favor Of Proposal One And Two
Benzinga · 11/22 21:08
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024
Barchart · 11/22 15:05
Weekly Report: what happened at NBY last week (1111-1115)?
Weekly Report · 11/18 12:08
ISS supports NovaBay proposals to sell Avenova business
TipRanks · 11/15 13:15
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand
Barchart · 11/15 07:00
NovaBay Pharmaceuticals Reports Q3 2024 Financials Amid Strategic Changes
TipRanks · 11/15 04:22
NovaBay Is Maintained at Buy by Ascendiant Capital
Dow Jones · 11/11 17:53
Ascendiant Capital Maintains Buy on NovaBay Pharmaceuticals, Adjusts Price Target To $0.85 (1-35 Reverse Stock Split)
Benzinga · 11/11 17:44
Weekly Report: what happened at NBY last week (1104-1108)?
Weekly Report · 11/11 12:28
Based on the provided financial report article, the title of the article is likely: "10-Q: Nuvo Beauty, Inc. (NBY) Q3 2024 Earnings Report" This title is inferred based on the format of the article, which appears to be a quarterly earnings report filed with the Securities and Exchange Commission (SEC) in the form of a 10-Q filing. The article includes financial statements, notes, and other information related to Nuvo Beauty, Inc.'s (NBY) Q3 2024 earnings.
Press release · 11/08 07:46
NovaBay GAAP EPS of -$0.60 misses by $0.30, revenue of $2.44M misses by $0.19M
Seeking Alpha · 11/08 05:01
NovaBay accepts higher PRN offer, says Refresh deal no longer superior
Seeking Alpha · 11/06 21:49
NovaBay accepts revised transaction proposal from PRN
TipRanks · 11/06 21:34
*NovaBay: Entered Into an Amendment to the Asset Purchase Agreement to Increase Purchase Price>NBY
Dow Jones · 11/06 21:20
More
Webull provides a variety of real-time NBY stock news. You can receive the latest news about Novabay Pharma through multiple platforms. This information may help you make smarter investment decisions.
About NBY
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and wound care products. Its product, Avenova Antimicrobial Lid and Lash Solution, has antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. It offers a portfolio of products for each step of the standard at home treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. It also manufactures and sells its proprietary form of hypochlorous acid for the wound care market with its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers and other injuries.